WX [WuXi PharmaTech (Cayman)] 6-K: Form 6-K TABLE OF CONTENTS Page 3 4
[Form 6-K TABLE OF CONTENTS Page 3 4]
CPHI [CHINA PHARMAS,] DEF 14A: (Original Filing)
[SCHEDULE 14A INFORMATION o Check the appropriate box: o Preliminary Proxy Statement o Definitive Proxy Statement o Definitiveditional Materials o CHINA PHARMAS, Payment of Filing Fee (Check the appropriate box): o No fee required. o Feemputed on table below per Exchange Act Rules14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction]
TPI [TIANYIN PHARMACEUTICAL] SC 13D/A: FORM OF RULE 10B5-1 TRADING PLAN October 11,
[FORM OF RULE 10B5-1 TRADING PLAN October 11, 2010 This Trading Plan (the “Trading Plan”) is entered into on Time Poly Management Limited Tianyin Pharmaceutical Co., Inc. TPI between Seller and UBSFS agree as follows: 1. Specific Plan of Sale 2. Fees/Commissions 0.05 3. (a) (b) All investment decisions on behalf of Seller, including without limitation, decisions to purchase or] [(Amendment No. 3) TIANYIN PHARMACEUTICAL CO., INC. (Name of Issuer) SCHEDULE 13D/A Common Stock, $.001 par value (Title of Class of Securities) 88630M104 (CUSIP Number) Time Poly Management Ltd. Unit 06, 21/F, Beautiful Group Tower, 77 Connaught Road, Central, Hong Kong Telephone: (852) 3583 3340; Fax: (852) 3585 6021 (Name, Address and Telephone Number of Person Authorized to Receive Notices]
WX [WuXi PharmaTech (Cayman)] 6-K: (Original Filing)
[WuXi PharmaTech (Cayman) Inc. Form 6-K Page 3 4]
CPHI [CHINA PHARMAS,] DEF 14A: SCHEDULE 14A INFORMATION o Check the appropriate box:
[SCHEDULE 14A INFORMATION o Check the appropriate box: o Preliminary Proxy Statement o Definitive Proxy Statement o Definitiveditional Materials o CHINA PHARMAS, Payment of Filing Fee (Check the appropriate box): o No fee required. o Feemputed on table below per Exchange Act Rules14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction]
WX [WuXi PharmaTech (Cayman)] 6-K: WuXi PharmaTech (Cayman) Inc. Form 6-K Page 3
[WuXi PharmaTech (Cayman) Inc. Form 6-K Page 3 4]
CPHI [CHINA PHARMAS,] 10-Q: (Original Filing)
[FORM 10-Q (Mark One) x September 30, 2010 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMA HOLDINGS, INC. Delaware 73-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86 898-6681-1730 (China) (Issuer's telephone number, including area code)] [Hainan Helpson Medical & Biotechnology Co., Ltd. Long-term Labor Contract Employer: Hainan Helpson Medical & Biotechnology Co., Ltd. (hereunder called Party A or Company) Zhilin Li Legal Representative/ authorised agent: Unit 8, D Area, Office Hall, Haikou Bonded Zone, Haikou Party A's address: 570216 Post Code: Zhilin Li (hereunder called Party B) Employee: Female Sex: 57 Age: Bachelor Education Level:] [CERTIFICATION I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Frank Waung, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: November 10, 2010 -------------------------------- President and Chief Executive Officer EX-32.1 5 cphi10qex321093010.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: November 10, 2010 --------------------- (principal financial officer and principal accounting officer) EX-32.2 6 cphi10qex322093010.htm]
CPHI [CHINA PHARMAS,] 10-Q: FORM 10-Q (Mark One) x September 30, 2010
[FORM 10-Q (Mark One) x September 30, 2010 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMA HOLDINGS, INC. Delaware 73-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86 898-6681-1730 (China) (Issuer's telephone number, including area code)] [Hainan Helpson Medical & Biotechnology Co., Ltd. Long-term Labor Contract Employer: Hainan Helpson Medical & Biotechnology Co., Ltd. (hereunder called Party A or Company) Zhilin Li Legal Representative/ authorised agent: Unit 8, D Area, Office Hall, Haikou Bonded Zone, Haikou Party A's address: 570216 Post Code: Zhilin Li (hereunder called Party B) Employee: Female Sex: 57 Age: Bachelor Education Level:] [CERTIFICATION I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Frank Waung, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: November 10, 2010 -------------------------------- President and Chief Executive Officer EX-32.1 5 cphi10qex321093010.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: November 10, 2010 --------------------- (principal financial officer and principal accounting officer) EX-32.2 6 cphi10qex322093010.htm]
SVA [SINOVAC BIOTECH] SC 13G: (Original Filing)
[(Name of Issuer) Common Stock (Title of Class of Securities) P8696W104 (CUSIP Number) October 31, 2010 (Date of Event Which Requires Filing of this Statement) [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * CUSIP No. P8696W104 1. NAMES OF REPORTING PERSONS 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 3. SEC USE ONLY]
SVA [SINOVAC BIOTECH] SC 13G: (Name of Issuer) Common Stock (Title of Class
[(Name of Issuer) Common Stock (Title of Class of Securities) P8696W104 (CUSIP Number) October 31, 2010 (Date of Event Which Requires Filing of this Statement) [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * CUSIP No. P8696W104 1. NAMES OF REPORTING PERSONS 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 3. SEC USE ONLY]
